{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:17Z","timestamp":1793318177652,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The fractional exhaled nitric oxide (FeNO) level significantly correlates with eosinophilic airway inflammation and is considered a useful biomarker to guide inhaled corticosteroid (ICS) treatment in chronic obstructive pulmonary disease (COPD). This study investigated the FeNO response to ICS therapy in patients with COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Pubmed, Embase, and Cochrane Central Register were searched for relevant trials. The primary outcome measure was the change in FeNO after ICS treatment in COPD. Subgroup analysis was performed to identify factors affecting FeNO responsiveness. Also, we investigated the association between FeNO reduction and improvements in lung function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 6 clinical trials comprising 9 study arms and 258 patients were included in the analysis. The pooled estimates demonstrated a significant reduction in FeNO levels following ICS treatment (mean difference \u22126.30 parts per billion [ppb]; 95% confidence interval [CI], \u221210.46 to \u22122.14). This reduction was more enhanced in the high baseline FeNO group (\u226525\u2005ppb), with a mean difference of \u221214.59\u2005ppb (95% CI, \u221220.38 to \u22128.80). Meta-regression analysis identified baseline FeNO level as the only significant moderator of treatment response. Furthermore, in the high baseline FeNO group, ICS therapy led to a significant improvement in trough forced expiratory volume in 1 second at 12 weeks (mean difference 0.13\u2005L; 95% CI, 0.06\u20130.20).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings suggest that ICS therapy significantly reduces FeNO levels in COPD patients. High baseline FeNO may serve as a useful predictor of treatment response, as ICS tended to improve forced expiratory volume in 1 second in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044307","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:02:44Z","timestamp":1757970164000},"page":"e44307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of fractional exhaled nitric oxide response to inhaled corticosteroid therapy in chronic obstructive pulmonary disease: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-7099","authenticated-orcid":false,"given":"Jonghoo","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-7037","authenticated-orcid":false,"given":"Jae-Uk","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","article-title":"Global initiative for chronic obstructive lung disease 2023 Report: GOLD executive summary.","volume":"61","author":"Agusti","year":"2023","journal-title":"Eur Respir J"},{"key":"R2-20260923","first-page":"CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease.","volume":"2012","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"29596","DOI":"10.1074\/jbc.M102417200","article-title":"Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation.","volume":"276","author":"Okamoto","year":"2001","journal-title":"J Biol Chem"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-019-1130-y","article-title":"Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.","volume":"20","author":"Vogelmeier","year":"2019","journal-title":"Respir Res"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.amjms.2020.04.038","article-title":"Fraction of exhaled nitric oxide is elevated in patients with stable chronic obstructive pulmonary disease: a meta-analysis.","volume":"360","author":"Gong","year":"2020","journal-title":"Am J Med Sci"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.arbres.2021.11.013","article-title":"Fractional exhaled nitric oxide guided-therapy in chronic obstructive pulmonary disease: a stratified, randomized, controlled trial.","volume":"58","author":"Su","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"BJGPO.2022.0105","DOI":"10.3399\/BJGPO.2022.0105","article-title":"Effectiveness of exhaled nitric oxide for the prediction of non-invasive left atrial pressure in older people: a cross-sectional cohort study.","volume":"7","author":"Jone","year":"2022","journal-title":"BJGP Open"},{"key":"R10-20260923","first-page":"1428","article-title":"Update on the role of FeNO in asthma management.","volume":"13","author":"Murugesan","year":"2023","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.","volume":"58","author":"Deeks","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.cgh.2006.09.009","article-title":"Portal hypertension and hepatocellular carcinoma: prognosis and beyond.","volume":"4","author":"Tandon","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-20260923","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fphar.2011.00036","article-title":"Improvement of airflow limitation by fluticasone propionate\/salmeterol in chronic obstructive pulmonary disease: what is the specific marker?","volume":"2","author":"Akamatsu","year":"2011","journal-title":"Front Pharmacol"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1378\/chest.11-2535","article-title":"Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol.","volume":"142","author":"Scherr","year":"2012","journal-title":"Chest"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"e11922","DOI":"10.1097\/MD.0000000000011922","article-title":"Treatment of chronic obstructive pulmonary disease in patients with different fractional exhaled nitric oxide levels.","volume":"97","author":"Wu","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"026007","DOI":"10.1088\/1752-7163\/ab71a4","article-title":"Detection of type 2 biomarkers for response in COPD.","volume":"14","author":"Yamaji","year":"2020","journal-title":"J Breath Res"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.rmed.2004.12.008","article-title":"The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease.","volume":"99","author":"Zietkowski","year":"2005","journal-title":"Respir Med"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment.","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur Respir J"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/cea.14359","article-title":"Effectiveness of FeNO-guided treatment in adult asthma patients: a systematic review and meta-analysis.","volume":"53","author":"Korevaar","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.niox.2016.02.003","article-title":"Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes.","volume":"54","author":"Alcazar-Navarrete","year":"2016","journal-title":"Nitric Oxide"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1753465808088902","article-title":"Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.","volume":"2","author":"Kunisaki","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"1177271917730306","DOI":"10.1177\/1177271917730306","article-title":"Inhaled steroids and active smoking drive chronic obstructive pulmonary disease symptoms and biomarkers to a greater degree than airflow limitation.","volume":"12","author":"Silkoff","year":"2017","journal-title":"Biomark Insights"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"00686","DOI":"10.1183\/23120541.00686-2023","article-title":"Exhaled nitric oxide, eosinophils and current smoking in COPD patients.","volume":"9","author":"Higham","year":"2023","journal-title":"ERJ Open Res"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1164\/rccm.200905-0685OC","article-title":"Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide.","volume":"180","author":"Dummer","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:52Z","timestamp":1790186572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":25,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044307","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2025-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}